TY  - GEN
AU  - Patton, E Elizabeth
AU  - Mueller, Kristen L
AU  - Adams, David J
AU  - Anandasabapathy, Niroshana
AU  - Aplin, Andrew E
AU  - Bertolotto, Corine
AU  - Bosenberg, Marcus
AU  - Ceol, Craig J
AU  - Burd, Christin E
AU  - Chi, Ping
AU  - Herlyn, Meenhard
AU  - Holmen, Sheri L
AU  - Karreth, Florian A
AU  - Kaufman, Charles K
AU  - Khan, Shaheen
AU  - Kobold, Sebastian
AU  - Leucci, Eleonora
AU  - Levy, Carmit
AU  - Lombard, David B
AU  - Lund, Amanda W
AU  - Marie, Kerrie L
AU  - Marine, Jean-Christophe
AU  - Marais, Richard
AU  - McMahon, Martin
AU  - Robles-Espinoza, Carla Daniela
AU  - Ronai, Ze'ev A
AU  - Samuels, Yardena
AU  - Soengas, MS
AU  - Villanueva, Jessie
AU  - Weeraratna, Ashani T
AU  - White, Richard M
AU  - Yeh, Iwei
AU  - Zhu, Jiyue
AU  - Zon, Leonard I
AU  - Hurlbert, Marc S
AU  - Merlino, Glenn
PY  - 2021
UR  - https://hdl.handle.net/20.500.12105/25366
AB  - There is a lack of appropriate melanoma models that can be used to evaluate the efficacy of novel therapeutic modalities. Here, we discuss the current state of the art of melanoma models including genetically engineered mouse, patient-derived...
LA  - eng
PB  - Cell Press
KW  - animal models
KW  - drug discovery
KW  - immunotherapy
KW  - melanoma
KW  - targeted therapy
KW  - therapeutics
KW  - tumor microenvironment
TI  - Melanoma models for the next generation of therapies.
TY  - research article
ER  -